Which peptides are studied for inflammation and immune conditions?
Short answer
8 profiles here are grouped under “Inflammation and immune”: 4 FDA-approved and 4 not FDA-approved.
Each entry below quotes its profile and links to the full answer there.
FDA-approved 4
Glatiramer acetate
Not a single peptide: a mixture often looked up alongside peptides
FDA-approved as Empaveli for PNH and two complement-driven kidney diseases5,6
FDA-approved. Drugs@FDA lists Empaveli, NDA 215014, approved May 14, 2021, and a second pegcetacoplan product, Syfovre, NDA 217171, approved February 17, 2023. The Empaveli label has a boxed warning about serious infections.5,6,7
Not FDA-approved 4
Not an FDA-approved drug10
Not FDA-approved. FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, KPV acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.10,11,12
Not FDA-approved; FDA advised against adding it to the compounding list13,15,16
Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.13,15
Is thymosin alpha-1 FDA-approved? · Thymosin alpha-1 vs Thymosin beta-4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Drugs@FDA: COPAXONE (glatiramer acetate), NDA 020622 · original approval December 20, 1996 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 2COPAXONE (glatiramer acetate injection) · SPL version 36 · published 2026-06-26 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
- 3FIRAZYR (icatibant acetate) injection, solution · SPL version 19 · published 2025-07-17 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 4Drugs@FDA: FIRAZYR (icatibant acetate), NDA 022150 · original approval August 25, 2011 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 5EMPAVELI (pegcetacoplan) injection · SPL version 14 · published 2026-08-25 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 6Drugs@FDA: EMPAVELI (pegcetacoplan), NDA 215014 · original approval May 14, 2021 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 7Drugs@FDA: SYFOVRE (pegcetacoplan), NDA 217171 · original approval February 17, 2023 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 8ZILBRYSQ (zilucoplan) injection, solution · SPL version 13 · published 2026-02-05 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 9Drugs@FDA: ZILBRYSQ (zilucoplan sodium), NDA 216834 · original approval October 17, 2023 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 10FDA briefing document for KPV ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 11Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 12HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 13Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 14Thymopentin substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 15FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 16December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026